Developer docs
API playgroundTry for free, no card

Search company profiles

Orthobond

Full company profile

uuid0009bce

Namestring
Orthobond
Legal namestring
Orthobond Corporation
Websiteurl
orthobond.com
Company typeenum
Private
Founded yearint
2009
Descriptiontext

Orthobond Corporation is a privately held biotechnology company headquartered in Monmouth Junction, New Jersey, that develops proprietary antimicrobial nanosurface coatings for medical implantable devices. Its core product, Ostaguard™, is a covalent, non-eluting surface treatment less than 100 nanometers thick that uses phosphonate linkers and quaternary ammonium compounds to mechanically rupture pathogens — including bacteria, viruses, and fungi — without antibiotics or eluting chemicals. The technology has demonstrated 99.99% effectiveness against a broad spectrum of pathogens including S. aureus, MRSA, S. epidermidis, P. acnes, P. aeruginosa, E. coli, and C. albicans, and can be applied to existing metallic and polymeric medical devices without requiring design changes.

Orthobond operates a B2B technology licensing model, partnering with medical device manufacturers who integrate Ostaguard into their FDA-cleared products. The company provides end-to-end services including development expertise, regulatory pathway support, and contract manufacturing at its 8,000 square-foot facility, guiding partners from contract completion to FDA submission within approximately 18 months. Named commercial partners include SeaSpine (Mariner Pedicle Screw System for spinal fusion) and Onkos Surgical (oncology/limb salvage implants), both of which received FDA De Novo clearances in April 2024 for Ostaguard-coated products — the first FDA approvals ever granted for a non-eluting antibacterial coating on permanent medical implants.

The company originated from research at Princeton University, was founded around 2009, and has raised approximately $47 million in cumulative funding over 15 years from top-tier angel investors, strategic partners, private grants, and the Kineticos AMR Accelerator Fund I (September 2024). Orthobond identifies broader addressable markets beyond medical devices including textiles, consumer goods, automotive, and high-touch public surfaces. The company operates with 1-10 employees under CEO David Nichols, with Chairman Eric Major (appointed July 2024), Chief Medical Officer Frank P. Cammisa, MD, and Chief Scientific Officer Jordan Katz, Ph.D.

Short descriptiontext

Orthobond is a biotechnology company that develops and licenses Ostaguard™, a proprietary non-eluting antibacterial nanosurface coating for medical implantable devices, partnering with medical device manufacturers to integrate antibacterial protection into their FDA-cleared products.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMonmouth Junction, United States
HQ citystring
Monmouth Junction
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antibacterial surface coatings, antimicrobial medical devices, implant infection prevention, nanosurface technology, FDA cleared coatings
Industry1 code
PRIMARYHLAHAEAB
Orthopedic Trauma & Extremities Fixation (Plates/Screws/Nails/External Fixation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
NAICS code1 code
  • Surgical Appliance and Supplies Manufacturing339113
SIC code1 code
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Antimicrobial Medical Device Surface Technology
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Technology Licensing to Medical Device Manufacturers
TypeLicensing Royalties
Description

Orthobond licenses its Ostaguard antibacterial coating technology to medical device manufacturers who want to add antibacterial protection to their existing FDA-cleared devices without redesigning them. The company provides development expertise, regulatory support, and manufacturing services.

orthobond.com
2Contract Manufacturing and Application Services
TypeProfessional Services
Description

Orthobond applies the Ostaguard coating to partners' devices at their 8,000 square-foot facility in Monmouth Junction, NJ. This includes pre-market testing with established protocol of safety and efficacy tests for FDA-regulated medical devices.

orthobond.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Others
Pricing details1 tier
1B2B contract-based pricing for medical device manufacturer partnerships
ModelOtherBilling cadenceMulti-year contract
Notes

Quote-based / Not publicly disclosed. Pricing varies based on device type, volume, regulatory pathway requirements, and partnership scope.

orthobond.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1Ostaguard
Description

Proprietary antibacterial surface treatment technology that kills bacteria, viruses, and fungi by mechanically rupturing pathogens without using antibiotics. First FDA De Novo approved non-eluting coating for medical devices with initial application in orthopedic spinal implants.

orthobond.com
Core offering1 text field

Orthobond develops and licenses Ostaguard™, a proprietary antibacterial nanosurface coating applied to medical implants during manufacturing. The covalent, non-eluting surface treatment mechanically ruptures bacteria, viruses, and fungi on contact without antibiotics or eluting chemicals, and can be permanently bound to metallic and polymeric surfaces. The company partners with medical device manufacturers to apply the coating and provide regulatory and manufacturing support, guiding partners from contract to FDA submission within 18 months.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 99.99% effective in killing multiple strains of bacteria that could come in contact with an implant in the operating room
+4 more records
Product overview1 text field

Orthobond is an antimicrobial technology company offering proprietary antibacterial nanosurface technology. Their core product is Ostaguard™, a first-of-its-kind FDA De Novo-approved antibacterial surface coating that mechanically kills pathogens without using antibiotics or eluting chemicals. The technology can be applied to existing medical devices during manufacturing without requiring design changes. Initial applications focus on orthopedic spinal implants, with expansion into trauma, cardiovascular, oncology, plastic surgery, dental, and neuromodulation. The company operates an 8,000 square-foot manufacturing facility and provides regulatory pathway support for device manufacturers seeking FDA clearance for Ostaguard-coated products.

Product and service1 record
1Ostaguard™
CategoryAntibacterial surface coating
Description

Ostaguard™ is a proprietary antibacterial surface treatment that mechanically kills bacteria, viruses, and fungi on medical implants by rupturing pathogens without using antibiotics. It is the first FDA De Novo-classified non-eluting coating for permanent medical devices, applied during manufacturing prior to packaging and sterilization, and effective at killing 99.99% of bacteria that contact an implantable device. The coating is targeted at medical device manufacturers across orthopedics, spine, trauma, cardiovascular, oncology, dental, plastic surgery, and neuromodulation categories.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-04-01
Description

SeaSpine received FDA De Novo clearance for their Mariner Pedicle Screw System with Orthobond's Ostaguard antibacterial coating - the first Ostaguard-coated product to receive FDA approval. SeaSpine manufactures and commercializes the coated pedicle screws for spinal fusion procedures.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-04-01
Description

Onkos Surgical received separate FDA De Novo approval for orthopedic implants with Orthobond's Ostaguard antibacterial coating for limb salvage procedures. Onkos Surgical developed and manufactures the coated implants and reported the first successful surgeries using the technology.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

MCRA partnered with Orthobond to achieve FDA De Novo clearance for the SeaSpine Mariner Pedicle Screw System with Ostaguard coating. MCRA provided regulatory consulting and clinical expertise for the FDA clearance process.

Strategic tierFoundationalTypeStrategic or Co-development Partner
Description

Orthobond's original platform technology was first developed at Princeton University with the intention of improving the performance of medical devices. The company emerged from over a decade of research, experimentation, collaboration, and persistence originating from this academic partnership.

5Three Prestigious Universities
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Orthobond works closely with three prestigious universities in addition to their Princeton origins for ongoing research and development collaboration in chemistry, biomaterials, and microbiology.

orthobond.com
6Leading Chemical Industry Companies
Strategic tierSupportingTypeTechnology or Integration
Description

Orthobond collaborates with the most prominent companies in the chemical industry for raw materials and specialty chemicals needed for their proprietary coating application process.

orthobond.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Canadian company commercializing antimicrobial and biocompatible coatings for medical devices including IV catheters, dressings, and surgical implants. Direct competitor applying surface modification technologies to infection prevention on medical devices.

TypeDirect peer
Description

UK-based developer of biocompatible and antimicrobial polymer coatings for medical devices including stents, catheters, and implants. Direct peer in delivering regulatory-cleared surface treatments that prevent device-related infection and thrombosis.

TypeBroad incumbent
Description

US-based provider of surface modification coating technologies for in vitro diagnostics, medical devices, and drug delivery. Broad incumbent in medical device coatings with established regulatory and licensing infrastructure that overlaps with Orthobond's OEM partnership model.

TypeDirect peer
Description

Provider of antimicrobial technologies (formerly Agion Technologies) for medical devices, healthcare textiles, and consumer products. Direct peer in commercializing silver- and quaternary-ammonium-based antimicrobial surface treatments across healthcare and industrial segments.

TypeDirect peer
Description

Specialty company developing antimicrobial coating technologies for medical devices including orthopedic implants and surgical instruments. Direct peer focused on preventing device-related infections through novel surface chemistry — overlapping scientific approach with Ostaguard.

TypeDirect peer
Description

Developer of hydrogel and antimicrobial coatings for medical devices including catheters, guidewires, and implants. Direct peer applying surface modification technologies licensed to medical device manufacturers for infection prevention.

TypeDirect peer
Description

Provider of surface treatment and coating services for medical devices, including antimicrobial and biocompatible coatings on implants and instruments. Direct peer serving OEM medical device customers with regulatory-cleared surface modification technologies.

8Covestro (formerly DSM Biomedical)
TypeBroad incumbent
Description

Major materials science company (including legacy DSM Biomedical) supplying biocompatible coatings, polymers, and surface treatments for medical devices and implants. Broad incumbent with extensive R&D and global manufacturing footprint relevant to large-scale OEM partnerships.

TypeBroad incumbent
Description

Global specialty chemical company providing built-in antimicrobial technologies for healthcare, consumer, and industrial products. Broad incumbent with established brand and licensing infrastructure relevant to Orthobond's longer-term consumer/industrial ambitions.

TypeDirect peer
Description

Provider of surface treatment and coating technologies for medical devices including hydrophilic, antimicrobial, and drug-eluting coatings. Direct peer serving medical device OEMs with contract coating application services analogous to Orthobond's contract manufacturing model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Orthobond

Antimicrobial Medical Device Surface Technologyorthobond.com

Orthobond is a biotechnology company that develops and licenses Ostaguard™, a proprietary non-eluting antibacterial nanosurface coating for medical implantable devices, partnering with medical device manufacturers to integrate antibacterial protection into their FDA-cleared products.

What Orthobond does

Orthobond Corporation is a privately held biotechnology company headquartered in Monmouth Junction, New Jersey, that develops proprietary antimicrobial nanosurface coatings for medical implantable devices. Its core product, Ostaguard™, is a covalent, non-eluting surface treatment less than 100 nanometers thick that uses phosphonate linkers and quaternary ammonium compounds to mechanically rupture pathogens — including bacteria, viruses, and fungi — without antibiotics or eluting chemicals. The technology has demonstrated 99.99% effectiveness against a broad spectrum of pathogens including S. aureus, MRSA, S. epidermidis, P. acnes, P. aeruginosa, E. coli, and C. albicans, and can be applied to existing metallic and polymeric medical devices without requiring design changes.

Orthobond operates a B2B technology licensing model, partnering with medical device manufacturers who integrate Ostaguard into their FDA-cleared products. The company provides end-to-end services including development expertise, regulatory pathway support, and contract manufacturing at its 8,000 square-foot facility, guiding partners from contract completion to FDA submission within approximately 18 months. Named commercial partners include SeaSpine (Mariner Pedicle Screw System for spinal fusion) and Onkos Surgical (oncology/limb salvage implants), both of which received FDA De Novo clearances in April 2024 for Ostaguard-coated products — the first FDA approvals ever granted for a non-eluting antibacterial coating on permanent medical implants.

The company originated from research at Princeton University, was founded around 2009, and has raised approximately $47 million in cumulative funding over 15 years from top-tier angel investors, strategic partners, private grants, and the Kineticos AMR Accelerator Fund I (September 2024). Orthobond identifies broader addressable markets beyond medical devices including textiles, consumer goods, automotive, and high-touch public surfaces. The company operates with 1-10 employees under CEO David Nichols, with Chairman Eric Major (appointed July 2024), Chief Medical Officer Frank P. Cammisa, MD, and Chief Scientific Officer Jordan Katz, Ph.D.

Orthobond firmographics

Firmographics
Name
Orthobond
Legal name
Orthobond Corporation
Website
https://orthobond.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
11–50 employees
Short description
Orthobond is a biotechnology company that develops and licenses Ostaguard™, a proprietary non-eluting antibacterial nanosurface coating for medical implantable devices, partnering with medical device manufacturers to integrate antibacterial protection into their FDA-cleared products.
Ownership category
akta.pro rank

Orthobond industry classification

Industry
Product category
Antimicrobial Medical Device Surface Technology
NAICS
Surgical Appliance and Supplies Manufacturing (339113)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAHAEAB
Orthopedic Trauma & Extremities Fixation (Plates/Screws/Nails/External Fixation)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)

Keywords

  • Antibacterial surface coatings
  • Antimicrobial medical devices
  • Implant infection prevention
  • Nanosurface technology
  • FDA cleared coatings

Where Orthobond is headquartered

Location

Headquarters

HQ city
Monmouth Junction
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Orthobond business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Others

Revenue model

  1. Technology Licensing to Medical Device Manufacturers: Orthobond licenses its Ostaguard antibacterial coating technology to medical device manufacturers who want to add antibacterial protection to their existing FDA-cleared devices without redesigning them. The company provides development expertise, regulatory support, and manufacturing services.
  2. Contract Manufacturing and Application Services: Orthobond applies the Ostaguard coating to partners' devices at their 8,000 square-foot facility in Monmouth Junction, NJ. This includes pre-market testing with established protocol of safety and efficacy tests for FDA-regulated medical devices.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractB2B contract-based pricing for medical device manufacturer partnerships

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Orthobond product offering

Product offering

Core offering

Orthobond develops and licenses Ostaguard™, a proprietary antibacterial nanosurface coating applied to medical implants during manufacturing. The covalent, non-eluting surface treatment mechanically ruptures bacteria, viruses, and fungi on contact without antibiotics or eluting chemicals, and can be permanently bound to metallic and polymeric surfaces. The company partners with medical device manufacturers to apply the coating and provide regulatory and manufacturing support, guiding partners from contract to FDA submission within 18 months.

Product overview

Orthobond is an antimicrobial technology company offering proprietary antibacterial nanosurface technology. Their core product is Ostaguard™, a first-of-its-kind FDA De Novo-approved antibacterial surface coating that mechanically kills pathogens without using antibiotics or eluting chemicals. The technology can be applied to existing medical devices during manufacturing without requiring design changes. Initial applications focus on orthopedic spinal implants, with expansion into trauma, cardiovascular, oncology, plastic surgery, dental, and neuromodulation. The company operates an 8,000 square-foot manufacturing facility and provides regulatory pathway support for device manufacturers seeking FDA clearance for Ostaguard-coated products.

Differentiator

Problem solved

Functional benefit

Brands

  • Ostaguard: Proprietary antibacterial surface treatment technology that kills bacteria, viruses, and fungi by mechanically rupturing pathogens without using antibiotics. First FDA De Novo approved non-eluting coating for medical devices with initial application in orthopedic spinal implants.

Products and services

  • Ostaguard™ Ostaguard™ is a proprietary antibacterial surface treatment that mechanically kills bacteria, viruses, and fungi on medical implants by rupturing pathogens without using antibiotics. It is the first FDA De Novo-classified non-eluting coating for permanent medical devices, applied during manufacturing prior to packaging and sterilization, and effective at killing 99.99% of bacteria that contact an implantable device. The coating is targeted at medical device manufacturers across orthopedics, spine, trauma, cardiovascular, oncology, dental, plastic surgery, and neuromodulation categories.

Quantifiable outcome

  • 99.99% effective in killing multiple strains of bacteria that could come in contact with an implant in the operating room
  • +4 more outcomes

Companies that use Orthobond

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles2 records

Orthobond technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Orthobond partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core, foundational and supporting.

  • SeaSpinecoreStrategic or Co-development Partner · 1 April 2024SeaSpine received FDA De Novo clearance for their Mariner Pedicle Screw System with Orthobond's Ostaguard antibacterial coating - the first Ostaguard-coated product to receive FDA approval. SeaSpine manufactures and commercializes the coated pedicle screws for spinal fusion procedures.
  • Onkos SurgicalcoreStrategic or Co-development Partner · 1 April 2024Onkos Surgical received separate FDA De Novo approval for orthopedic implants with Orthobond's Ostaguard antibacterial coating for limb salvage procedures. Onkos Surgical developed and manufactures the coated implants and reported the first successful surgeries using the technology.
  • MCRAcoreStrategic or Co-development Partner · 1 January 2024MCRA partnered with Orthobond to achieve FDA De Novo clearance for the SeaSpine Mariner Pedicle Screw System with Ostaguard coating. MCRA provided regulatory consulting and clinical expertise for the FDA clearance process.
  • Princeton UniversityfoundationalStrategic or Co-development PartnerOrthobond's original platform technology was first developed at Princeton University with the intention of improving the performance of medical devices. The company emerged from over a decade of research, experimentation, collaboration, and persistence originating from this academic partnership.
  • Three Prestigious UniversitiessupportingStrategic or Co-development PartnerOrthobond works closely with three prestigious universities in addition to their Princeton origins for ongoing research and development collaboration in chemistry, biomaterials, and microbiology.
  • Leading Chemical Industry CompaniessupportingTechnology or IntegrationOrthobond collaborates with the most prominent companies in the chemical industry for raw materials and specialty chemicals needed for their proprietary coating application process.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Orthobond competitors and assessment

Company assessment

Direct peers

  • Covalon Technologies: Canadian company commercializing antimicrobial and biocompatible coatings for medical devices including IV catheters, dressings, and surgical implants. Direct competitor applying surface modification technologies to infection prevention on medical devices.
  • BioInteractions: UK-based developer of biocompatible and antimicrobial polymer coatings for medical devices including stents, catheters, and implants. Direct peer in delivering regulatory-cleared surface treatments that prevent device-related infection and thrombosis.
  • Sciessent: Provider of antimicrobial technologies (formerly Agion Technologies) for medical devices, healthcare textiles, and consumer products. Direct peer in commercializing silver- and quaternary-ammonium-based antimicrobial surface treatments across healthcare and industrial segments.
  • N8 Medical: Specialty company developing antimicrobial coating technologies for medical devices including orthopedic implants and surgical instruments. Direct peer focused on preventing device-related infections through novel surface chemistry — overlapping scientific approach with Ostaguard.
  • Hydromer: Developer of hydrogel and antimicrobial coatings for medical devices including catheters, guidewires, and implants. Direct peer applying surface modification technologies licensed to medical device manufacturers for infection prevention.
  • AST Products: Provider of surface treatment and coating services for medical devices, including antimicrobial and biocompatible coatings on implants and instruments. Direct peer serving OEM medical device customers with regulatory-cleared surface modification technologies.
  • Harland Medical Systems: Provider of surface treatment and coating technologies for medical devices including hydrophilic, antimicrobial, and drug-eluting coatings. Direct peer serving medical device OEMs with contract coating application services analogous to Orthobond's contract manufacturing model.

Broad incumbents

  • Surmodics: US-based provider of surface modification coating technologies for in vitro diagnostics, medical devices, and drug delivery. Broad incumbent in medical device coatings with established regulatory and licensing infrastructure that overlaps with Orthobond's OEM partnership model.
  • Covestro (formerly DSM Biomedical): Major materials science company (including legacy DSM Biomedical) supplying biocompatible coatings, polymers, and surface treatments for medical devices and implants. Broad incumbent with extensive R&D and global manufacturing footprint relevant to large-scale OEM partnerships.
  • Microban International: Global specialty chemical company providing built-in antimicrobial technologies for healthcare, consumer, and industrial products. Broad incumbent with established brand and licensing infrastructure relevant to Orthobond's longer-term consumer/industrial ambitions.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Orthobond social profiles

Digital presence

Orthobond financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Orthobond leadership team

Management profile

Number of profiles

Profiles14 records

Orthobond funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Orthobond M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Orthobond

What does Orthobond do?

Orthobond develops and licenses Ostaguard™, a proprietary antibacterial nanosurface coating applied to medical implants during manufacturing. The covalent, non-eluting surface treatment mechanically ruptures bacteria, viruses, and fungi on contact without antibiotics or eluting chemicals, and can be permanently bound to metallic and polymeric surfaces. The company partners with medical device manufacturers to apply the coating and provide regulatory and manufacturing support, guiding partners from contract to FDA submission within 18 months.

Is Orthobond a public or private company?

Orthobond is a private company. It is classified as venture growth investor backed and is currently operating.

When was Orthobond founded?

Orthobond was founded in 2009. It employs 11 to 50 people.

Where is Orthobond based?

Orthobond is headquartered in Monmouth Junction, United States, in the North America region.

How does Orthobond make money?

Two revenue lines are on record. Technology Licensing to Medical Device Manufacturers are the primary driver. The others are contract Manufacturing and Application Services.

Who are Orthobond's main competitors?

Direct peers on record are Covalon Technologies, BioInteractions, Sciessent, N8 Medical, Hydromer, AST Products and Harland Medical Systems. Broad incumbents are Surmodics, Covestro (formerly DSM Biomedical) and Microban International.

Does Orthobond have an API?

No public API is recorded for Orthobond.

What industry is Orthobond in?

Orthobond's product category is Antimicrobial Medical Device Surface Technology. Its primary akta.pro industry code is HLAHAEAB, Orthopedic Trauma & Extremities Fixation (Plates/Screws/Nails/External Fixation). Its NAICS code is 339113 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Market Research & Business IntelligencePedicle Screw Systems Market Trends & Forecast 2025 to 2035The global pedicle screw systems market is valued at USD 5.45 billion in 2025 and is projected to reach USD 8.54 billion by 2035, growing at a CAGR of 4.6%, driven by rising spinal fusion surgeries, advancements in minimally invasive techniques, and increasing adoption of robotic-assisted procedures. In 2025, the USA FDA announced Eminent Spine's 3D Printed Titanium Pedicle Screw System clearance, while in 2024 MCRA partnered with Orthobond to achieve FDA De Novo clearance for the Mariner Pedicle Screw System with Ostaguard coating. Key market players including Medtronic, Stryker, DePuy Synthes, and Zimmer Biomet are advancing product pipelines through robotic integration and surgeon education programs, with North America leading the market due to high procedural volumes and favorable reimbursement structures.MedicaldesignandoutsourcingAntibacterial coating developer Orthobond reports first-in-human caseOrthobond reported its first-in-human case, with a medical device treated with its Ostaguard antibacterial coating surgically implanted in a patient. The technology won FDA de novo approvals in April 2024 for SeaSpine Mariner pedicle screws and implants, with Onkos Surgical reporting successful surgeries. The company plans to expand regulatory clearances beyond ELEOS to include orthopaedic reconstruction implants.KineticosThe Kineticos AMR Accelerator Fund I Invests in OrthobondKineticos Life Sciences announced an investment in Orthobond through its Kineticos AMR Accelerator Fund I to support the commercialization of Orthobond's Ostaguard™ antibacterial technology. This financing follows FDA approval for Orthobond's De Novo application for use in spine implants, enabling the company to expand into pedicle screw spinal surgery and pursue additional regulatory approvals. Steve Favaloro from Kineticos will join Orthobond’s Board of Directors to assist with this growth phase.PR NewswireThe Kineticos AMR Accelerator Fund I Invests in OrthobondKineticos Life Sciences announced an investment in Orthobond through its Kineticos AMR Accelerator Fund I to support the medical device company's growth and commercialization efforts. This funding follows Orthobond's recent FDA De Novo approval for Ostaguard™, an antibacterial surface technology for spine implants, which will help expand its market presence in implant surgery.PR NewswireMCRA Partner Orthobond Granted De Novo for Innovative Pedicle Screw System with Ostaguard™ CoatingOrthobond received FDA De Novo approval for its Mariner Pedicle Screw System featuring the Ostaguard antibacterial coating, marking the first spine device with a coating designed to reduce bacterial contamination. MCRA facilitated this regulatory milestone by managing the strategy and submission process for Orthobond. The approval allows for commercial use of the technology in the United States.FierceBiotechFDA delivers de novo clearances to 2 novel antibacterial implant coatingsThe FDA granted de novo clearances to two antibacterial implant coatings from Orthobond and Onkos Surgical. Orthobond's Ostaguard and Onkos's ELEOSx coating use quaternary ammonium compounds to kill bacteria on implants. Neither company has submitted clinical trial data on infection risk over time.MedicaldesignandoutsourcingHow Orthobond’s antimicrobial coating prevents contamination of medical devicesOrthobond has received FDA de novo approval for its Ostaguard antimicrobial coating, initially applied to pedicle screws and subsequently to an oncology device from Onkos Surgical. The technology covalently bonds a 4-5 nanometer layer of quaternary ammonium molecules to medical implants to mechanically kill microbes, including antibiotic-resistant strains like MRSA. Orthobond plans to scale manufacturing and submit a master file to facilitate regulatory review for other device developers wishing to utilize the coating.MassDeviceOrthobond wins FDA de novo approval for antibacterial technology that could have vast device applicationsOrthobond received FDA de novo approval for its Ostaguard antibacterial coating, the first non-eluting coating granted de novo for actively killing bacteria on medical devices. The first application is Ostaguard-treated SeaSpine Mariner pedicle screws, with use expected early next year. The company plans to seek 510(k) clearances for additional spinal implants and expand to other fields.GlobeNewswireOrthobond Corporation to Present at the 2017 North American Spine Society Annual MeetingOrthobond Corporation will present at the 2017 North American Spine Society Annual Meeting, focusing on occult infections in the spine. The company's covalent nanoscale technology creates antimicrobial surfaces with reduced bacterial resistance and toxicity. The presentation aims to share insights on bacterial-surface interactions with the clinical community.GlobeNewswireOrthobond Appoints New Chief Executive Officer and NewOrthobond Corporation appointed Charles Ryan as CEO and Marc Burel as COO. Ryan joins from Cold Spring Harbor Laboratory, while Burel has led the company since 2008. The company focuses on antimicrobial surfaces for medical implants.